Lung Cancer Tweeter feed from ECCO-ESMO 2011
Published: Wed Sep 28, 2011 Updated:Mon Oct 3, 2011We extend our thanks to Dr. Verma for providing live tweets from ECCO-ESMO 2011.
Vorinostat in Mesothelioma – presented by Dr. Lee Krug. The largest ever conducted trial in Mesothelioma: Vantage 014 #emcc2011
Vantage 014: No improvement in OS with Vorinostat in Mesothelioma (Vorinostat 31 wks vs Placebo 27 wks P=0.858) #emcc2011
VANTAGE 014: Key take away- be careful planning a large Phase III study based on results from Phase I study with a few patients #emcc2011
AVAPERL: Cis+Pem+Bev randomized to continued Bev vs. Bev+Pem in non-small cell #lung cancer #emcc2011
AVAPERL: N=253 randomized to Bev or Bev +Pem. Med f/up 11 months. PFS 10.2 m vs. 6.6 m P<0.001 #lung cancer #emcc2011
AVAPERL: OS data immature #lung cancer #emcc2011
Phase II study of Sorafenib in NSCLC with K-ras mutation: n=59, Efficacy – 16% RR, 37% SD. Non progression rate at 6 weeks – 57% #emcc2011
Sorafenib in NSCLC - author conclusions - need to look at subgroups of K-ras mutation most likely to benefit #emcc2011
Phase II study of Afatinib BIBW2992 in EGFR FISH +ve Non-Small Cell #Lung Cancer (Finocchiaro) #emcc2011
Response rate in 17% of patients and disease control in 48% of patients #lung cancer #emcc2011
